Alternatively, refractory tumors could be due to the elimination of only the tumor cells expressing CD20 with the CD20-negative cells surviving, suggesting intratumor heterogeneity that should be monitored during the course of treatment. The gene discussed is MS4A1; the disease is neoplasm.